



Lancaster 2405 Columbus Street Suite# 210 Lancaster, Ohio 43130

## Provider Order Form

## Iron (Feraheme/Injectafer/Venofer) Date: -

PAT	IENT IN	IFORMATION
Name:		DOB:
Allergies:		Date of Referral:
ICD-10 code (required):	ICD -10	description:
□ NKDA Allergies:		Weight lbs/kg:
Patient Status: □ New to Therapy □ Continuing Therapy <b>REFERRAL STATUS:</b> □ New Prescription □ Order Rene	Next Du	e Date (if applicable): oes or Frequency Change Discontinuation
•		NFORMATION
Referral Coordinator Name:	Referral	Coordinator Email:
Ordering Provider:	Provider	NPI:
Referring Practice Name:	Phone:	Fax:
Practice Address:	City:	State: Zip Code:
PREN-MEDICATION ORDERS		THERAPY ADMINISTRATION
<ul> <li>acetaminophen (Tylenol) □500mg / □650mg / □1000r</li> <li>cetirizine (Zyrtec) 10mg PO</li> <li>loratadine (Claritin) 10mg PO</li> <li>diphenhydramine (Benadryl) □ 25mg / □50mg □PO / □</li> <li>methylprednisolone (Solu-Medrol) □40mg / □125mg IV</li> <li>Other: Route:</li> <li>Frequency:</li> <li>SPECIAL INSTRUCTIONS</li> </ul>		<ul> <li>□ Ferumoxytol (Feraheme) intravenous infusion</li> <li>Dose &amp; Frequency: ☑initial 510mg infusion followed by a second 510mg infusion 3-8 days later</li> <li>□ Dilutein 50 - 200ml 0.9% sodium chloride or 5% dextros solution (final concentration 2mg - 8mg per ml)</li> <li>□ Infuse over at least 15 minutes</li> <li>□ No refills □ Other</li> <li>□ Ferriccarboxymaltose (Injectafer) intravenous infusion</li> <li>□ Dose &amp; Frequency:</li> <li>□ Patients &gt; 50kg: Two 750mg doses,7 days apart</li> <li>□ Patients &lt; 50kg: Two 15mg/kg doses, 7 days apart</li> <li>□ Dilute in no more than 250ml 0.9% sodium chloride</li> <li>□ Infuse over at least 15 minutes</li> <li>□ No refills □ Other</li> <li>□ Infuse over at least 15 minutes</li> <li>□ Dilute in no more than 250ml 0.9% sodium chloride</li> <li>□ Infuse over at least 15 minutes</li> <li>□ No refills □ Other</li> <li>□ Infuse over at least 15 minutes</li> <li>□ No refills □ Other</li> <li>□ Infuse over at least 15 minutes</li> <li>□ No refills □ Other</li> <li>□ Infuse over at least 15 minutes</li> <li>□ No refills □ Other</li> <li>□ Infuse over at least 15 minutes</li> <li>□ No refills □ Other</li> <li>□ Infuse over at least 15 minutes</li> <li>□ An orefills □ Other</li> <li>□ Infuse over at least 15 minutes</li> <li>□ An orefills □ Other</li> <li>□ Infuse over at least 15 minutes</li> <li>□ An orefills □ Other</li> <li>□ Infuse over 30 minutes</li> <li>□ 100mg in 100ml 0.9% sodium chloride over 30 minutes</li> <li>□ 300mg in 250ml 0.9% sodium chloride over 1.5 hours</li> <li>□ 400mg in 250ml 0.9% sodium chloride over 2.5 hours</li> <li>□</li> <li>■ Frequency:</li> </ul>
*Closely observe patients for signs and symptoms of hypersensitivity includir monitoring of blood pressure and pulse during and after Feraheme administr at least 30 minutes and until clinically stable following completion of each in *Observe for signs and symptoms of hypersensitivity during and after Injectar administration for at least 30 minutes and until clinically stable following co of each administration.*Monitor patients for signs and symptoms of hypersen during and after Venofer administration for at least 30 minutes and until clinically administration.*Monitor patients for signs and symptoms of hypersen during and after Venofer administration for at least 30 minutes and until clinically administration.*Monitor patients for signs and symptoms of hypersen during and after Venofer administration for at least 30 minutes and until clinically administration.*Monitor patients for signs and symptoms of hypersen during and after Venofer administration for at least 30 minutes and until clinically administration.*Monitor patients for signs and symptoms of hypersen during and after Venofer administration for at least 30 minutes and until clinically administration.*Monitor patients for signs and symptoms of hypersen during and after Venofer administration for at least 30 minutes and until clinically administration.*Monitor patients for signs and symptoms of hypersen during and after Venofer administration for at least 30 minutes and until clinically administration.*Monitor patients for signs and symptoms for signs and symptoms of hypersen administration.*Monitor patients for signs and symptoms for signs and s	ation for nfusion. fer mpletion nsitivity	<ul> <li>□ Once □Every 2-3 days x doses</li> <li>□ Daily x doses □Weekly x doses</li> <li>□ Monthly x doses □Other:</li> <li>□ Flush with 0.9% sodium chloride at the completion of infusio</li> <li>□ Patient required to stay for 30 - min observation period</li> <li>□ Total doses: □1 yr □Other</li> </ul>
Provider Name (Print) Provider Si	gnature	Date
ORDERING PROVIDER		
Signature X		Date
Provider	_ Pho	ne Fax